Computational Simulations to Guide Enzyme-Mediated Prodrug Activation

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 May 24

PMID 32443905

Citations 8

Authors

Milica Markovic

Shimon Ben-Shabat

Arik Dahan

Affiliations

Soon will be listed here.

Abstract

Prodrugs are designed to improve pharmaceutical/biopharmaceutical characteristics, pharmacokinetic/pharmacodynamic properties, site-specificity, and more. A crucial step in successful prodrug is its activation, which releases the active parent drug, exerting a therapeutic effect. Prodrug activation can be based on oxidation/reduction processes, or through enzyme-mediated hydrolysis, from oxidoreductases (i.e., Cytochrome P450) to hydrolytic enzymes (i.e., carboxylesterase). This study provides an overview of the novel in silico methods for the optimization of enzyme-mediated prodrug activation. Computational methods simulating enzyme-substrate binding can be simpler like molecular docking, or more complex, such as quantum mechanics (QM), molecular mechanics (MM), and free energy perturbation (FEP) methods such as molecular dynamics (MD). Examples for MD simulations used for elucidating the mechanism of prodrug (losartan, paclitaxel derivatives) metabolism via CYP450 enzyme are presented, as well as an MD simulation for optimizing linker length in phospholipid-based prodrugs. Molecular docking investigating quinazolinone prodrugs as substrates for alkaline phosphatase is also presented, as well as QM and MD simulations used for optimal fit of different prodrugs within the human carboxylesterase 1 catalytical site. Overall, high quality computational simulations may show good agreement with experimental results, and should be used early in the prodrug development process.

Citing Articles

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.

Mafe A, Busselberg D Biomedicines. 2025; 13(2).

PMID: 40002835 PMC: 11852609. DOI: 10.3390/biomedicines13020422.

Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy.

Parashar A, Saraogi G, Jain P, Kurmi B, Shrivastava V, Arora V Discov Oncol. 2024; 15(1):641.

PMID: 39527173 PMC: 11554983. DOI: 10.1007/s12672-024-01509-9.

Crocin-Phospholipid Complex: Molecular Docking, Molecular Dynamics Simulation, Preparation, Characterization, and Antioxidant Activity.

Rezaee Y, Rezaee E, Karami L, Torshabi M, Haeri A Iran J Pharm Res. 2024; 23(1):e144041.

PMID: 39005730 PMC: 11246643. DOI: 10.5812/ijpr-144041.

A cost-effective enzyme kinetics and inhibition model for biochemistry education and research.

VanDee L, Teague A, East T, Jacinto K, Carter M, Totty J Biochem Mol Biol Educ. 2024; 52(5):588-598.

PMID: 38877837 PMC: 11563930. DOI: 10.1002/bmb.21845.

The landscape of small-molecule prodrugs.

Fralish Z, Chen A, Khan S, Zhou P, Reker D Nat Rev Drug Discov. 2024; 23(5):365-380.

PMID: 38565913 DOI: 10.1038/s41573-024-00914-7.

References

Yarla N, Bishayee A, Vadlakonda L, Chintala R, Duddukuri G, Reddanna P . Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases. Curr Drug Targets. 2015; 17(16):1940-1962. DOI: 10.2174/1389450116666150727122501. View

Linderoth L, Andresen T, Jorgensen K, Madsen R, Peters G . Molecular basis of phospholipase A2 activity toward phospholipids with sn-1 substitutions. Biophys J. 2007; 94(1):14-26. PMC: 2134884. DOI: 10.1529/biophysj.107.110106. View

Sousa S, Ribeiro A, Coimbra J, Neves R, Martins S, Moorthy N . Protein-ligand docking in the new millennium--a retrospective of 10 years in the field. Curr Med Chem. 2013; 20(18):2296-314. DOI: 10.2174/0929867311320180002. View

Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M . Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut. 1994; 35(11):1593-8. PMC: 1375618. DOI: 10.1136/gut.35.11.1593. View

Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann E, Dahan A . Lipidic prodrug approach for improved oral drug delivery and therapy. Med Res Rev. 2018; 39(2):579-607. DOI: 10.1002/med.21533. View

Chen K, Aowad A, Adelstein S, Kassis A . Molecular-docking-guided design, synthesis, and biologic evaluation of radioiodinated quinazolinone prodrugs. J Med Chem. 2007; 50(4):663-73. DOI: 10.1021/jm060944k. View

Testa B, Kramer S . The biochemistry of drug metabolism--an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers. 2007; 4(3):257-405. DOI: 10.1002/cbdv.200790032. View

Kapetanovic I . Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact. 2007; 171(2):165-76. PMC: 2253724. DOI: 10.1016/j.cbi.2006.12.006. View

Barre A, Azzouz R, Gembus V, Papamicael C, Levacher V . Design, Synthesis, and In Vitro Biological Activities of a Bio-Oxidizable Prodrug to Deliver Both ChEs and DYRK1A Inhibitors for AD Therapy. Molecules. 2019; 24(7). PMC: 6479981. DOI: 10.3390/molecules24071264. View

10.

Mulholland A . Modelling enzyme reaction mechanisms, specificity and catalysis. Drug Discov Today. 2005; 10(20):1393-402. DOI: 10.1016/S1359-6446(05)03611-1. View

11.

Najjar A, Karaman R . The prodrug approach in the era of drug design. Expert Opin Drug Deliv. 2018; 16(1):1-5. DOI: 10.1080/17425247.2019.1553954. View

12.

Huttunen K, Raunio H, Rautio J . Prodrugs--from serendipity to rational design. Pharmacol Rev. 2011; 63(3):750-71. DOI: 10.1124/pr.110.003459. View

13.

Pedersen P, Adolph S, Subramanian A, Arouri A, Andresen T, Mouritsen O . Liposomal formulation of retinoids designed for enzyme triggered release. J Med Chem. 2010; 53(9):3782-92. DOI: 10.1021/jm100190c. View

14.

Dahan A, Ben-Shabat S, Cohen N, Keinan S, Kurnikov I, Aponick A . Phospholipid-Based Prodrugs for Drug Targeting in Inflammatory Bowel Disease: Computational Optimization and In-Vitro Correlation. Curr Top Med Chem. 2016; 16(23):2543-8. DOI: 10.2174/1568026616666160414122913. View

15.

Karaman R, Hallak H . Computer-assisted design of pro-drugs for antimalarial atovaquone. Chem Biol Drug Des. 2010; 76(4):350-60. DOI: 10.1111/j.1747-0285.2010.01018.x. View

16.

Dahan A, Markovic M, Keinan S, Kurnikov I, Aponick A, Zimmermann E . Computational modeling and in-vitro/in-silico correlation of phospholipid-based prodrugs for targeted drug delivery in inflammatory bowel disease. J Comput Aided Mol Des. 2017; 31(11):1021-1028. DOI: 10.1007/s10822-017-0079-5. View

17.

Sun J, Dahan A, Walls Z, Lai L, Lee K, Amidon G . Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm. 2010; 7(6):2362-8. PMC: 2997884. DOI: 10.1021/mp100300k. View

18.

Testa B . Prodrug research: futile or fertile?. Biochem Pharmacol. 2004; 68(11):2097-106. DOI: 10.1016/j.bcp.2004.07.005. View

19.

Dahan A, Zimmermann E, Ben-Shabat S . Modern prodrug design for targeted oral drug delivery. Molecules. 2014; 19(10):16489-505. PMC: 6271014. DOI: 10.3390/molecules191016489. View

20.

Hospital A, Goni J, Orozco M, Gelpi J . Molecular dynamics simulations: advances and applications. Adv Appl Bioinform Chem. 2015; 8:37-47. PMC: 4655909. DOI: 10.2147/AABC.S70333. View